Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 125 Show results per page	View Search Criteria \| Help With Results


1.		Iressa Case Control Study in Japan

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology				Completed				No age specified				Pharmaceutical / Industry				D791AL00002 V-15-33, OZV1533, NCT00252759


2.		SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				19 to 80				Pharmaceutical / Industry				D7913L00067 NCT00608868


3.		A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 to5				Pharmaceutical / Industry				1839IL/0143 NCT00234429

Last Modified: 7/1/2001 First Published: 7/1/2000


4.		Phase III Randomized Study of ZD 1839 Combined With Gemcitabine and Cisplatin in Chemotherapy Naive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer (Summary Last Modified 07/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				ZENECA-1839IL/0014 NCT00006048

Last Modified: 7/1/2001 First Published: 7/1/2000


5.		Phase III Randomized Study of ZD 1839 Combined With Paclitaxel and Carboplatin in Chemotherapy Naive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer (Summary Last Modified 07/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				ZENECA-1839IL/0017 MSKCC-00100, NCT00006049

Last Modified: 4/4/2008 First Published: 7/1/2001


6.		Phase III Randomized Study of Cisplatin, Etoposide, Radiotherapy, and Docetaxel With or Without Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				NCI				SWOG-S0023 CAN-NCIC-BR15, NCCTG-S0023, S0023, NCT00020709, BR15

Last Modified: 1/25/2008 First Published: 11/1/2002


7.		Phase III Randomized Study of Adjuvant Gefitinib in Patients With Completely Resected Primary Stage IB, II, or IIIA Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Other				CAN-NCIC-BR19 ECOG-CAN-NCIC-BR19, SWOG-CAN-NCIC-BR19, NCIC-BR.19, NCT00049543, BR19


8.		Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				TLK286.3020 NCT00080340

Last Modified: 11/14/2008 First Published: 7/23/2004


9.		Phase III Randomized Study of Docetaxel With or Without Gefitinib in Patients With Metastatic or Locally Recurrent Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				ECOG-E1302 E1302, NCT00088907

Last Modified: 7/28/2008 First Published: 8/24/2004


10.		Phase III Randomized Study of Adjuvant Gefitinib After Prior First-Line Palliative Induction Chemotherapy in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other				EORTC-08021 ILCP-01/03, EUDRACT-2004-001331-36, NCT00091156

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute